AbbVie's Qulipta Changes the Narrative Beyond the Humira Cliff

AbbVie's Qulipta Changes the Narrative Beyond the Humira Cliff Up 15.9% year-over-year to $1.968 billion, AbbVie's neuroscience portfolio is showing investors a path beyond the well-documented decline of its flagship drug, Humira. Led by the migraine treatment Qulipta, which saw sales grow 55.9%, the franchise's performance is forcing a re-evaluation of the company's prospects as it navigates one of the largest patent cliffs in pharmaceutical history. ## Background For years, AbbVie's stock was a one-drug story: Humira. The immunology blockbuster generated over $20 billion in annual revenue at its peak, but the loss of patent exclusivity has unleashed a wave of lower-cost biosimilar competitors. This so-called "patent cliff" has eroded Humira's sales, with revenue falling 35.9% in the first quarter of 2024 alone. For a company prized by income investors as a "Dividend King" for its history of consistently raising dividends, this revenue hole presents a fundamental threat to the earnings growth required to sustain its payout. The market has been intently focused on whether AbbVie's pipeline, particularly its next-generation immunology drugs Skyrizi and Rinvoq, could grow fast enough to offset Humira's decline. The recent strength of its neuroscience franchise adds a new, critical variable. This portfolio is competing in a crowded migraine market against other CGRP inhibitors, but Qulipta's commercial traction suggests AbbVie is effectively gaining share and building a third major growth pillar outside of immunology and oncology. ## Why it matters The read-through extends beyond AbbVie to the entire large-cap pharmaceutical sector. If a company can successfully navigate the loss of a drug that once accounted for nearly 40% of its total revenue, it provides a powerful case study for peers like Merck and Bristol-Myers Squibb, who face their own eventual patent cliffs for Keytruda and Eliquis. AbbVie's success would demonstrate that strategic acquisitions and a diversified, productive pipeline can indeed overcome the loss of a single megablockbuster. This narrative puts pressure on investors who are short the stock or remain skeptical of the post-Humira growth story. These positions are predicated on the idea that the revenue gap is simply too large to fill in the medium term. Continued outperformance from the ex-Humira platform, particularly the high-margin neuroscience assets, challenges that thesis directly. It also creates a problem for competitors in the migraine space who may be losing market share to AbbVie's determined commercial push. ## What to watch The next major catalyst is AbbVie's second-quarter earnings report, expected in late July 2024. The market will scrutinize the sales figures for Qulipta and the company's other growth drivers, Skyrizi and Rinvoq, measured against the continued erosion of Humira. The most critical data point will be any update to full-year 2024 guidance. An affirmation or, more importantly, an increase in the outlook for earnings per share (EPS), a measure of company profit per share of stock, would signal management's confidence that the growth platform is winning. A guidance cut or commentary suggesting a slowdown in the new franchises would validate bearish concerns.